Prognostic Value of Baseline High-Uptake PSMA Tumor Volume Fraction in Metastatic Castration-Resistant Prostate Cancer Patients Treated with [177Lu]Lu-PSMA Radioligand Therapy
Simple Summary Lutetium-177 prostate-specific membrane antigen radioligand therapy is an effective option for metastatic castration-resistant prostate cancer, yet a substantial proportion of patients progress early and no validated PSMA-PET/CT biomarker is available to identify them before treatment. In 63 patients, we...